Considerations for Treatment Sequencing in Primary Biliary Cholangitis
August 15th 2024In this video segment, Reau, Trivedi, and Hirschfield discuss how treatment sequencing in PBC has evolved over time with the emergence of new second-line therapies and considerations for determining sequencing.
Read More
Assessing PBC Treatment Options, Determining Sequencing
August 15th 2024In this video segment, Reau, Trivedi, and Hirschfield discuss the EMA opinion on obeticholic acid and its impact on discussions about second-line therapies amid the influx of new treatment options available for patients.
Read More
Practical Tips for the Primary Care Clinician Treating HE
Published: July 15th 2024 | Updated: July 15th 2024The group of hepatic encephalopathy (HE) professionals acknowledges the challenges and potential overwhelm faced by busy primary care practices when managing patients with HE, and they provide practical clinical pearls and advice to support these clinicians in delivering effective care and improving patient outcomes.
Read More
Managing Adverse Effects in HE Treatment
Published: July 8th 2024 | Updated: July 9th 2024Medical experts discuss the management of patients with hepatic encephalopathy (HE) receiving lactulose and rifaximin therapy and develop diarrhea or a urinary tract infection (UTI) in the outpatient setting.
Read More
AASLD Guidelines for Hepatic Encephalopathy: Rifaximin's Role and Safety
July 2nd 2024The panel reviews the current American Association for the Study of Liver Diseases (AASLD) guideline recommendations for treating patients with hepatic encephalopathy (HE), and they also discuss the role of rifaximin, its ability to be prescribed by primary care clinicians, and its safety profile.
Read More
Current Hepatic Encephalopathy Therapies Targeting Gut-Liver Axis Disturbance
July 2nd 2024Nancy Reau, MD, leads a discussion on the current abnormality-targeting agents used to prevent and treat hepatic encephalopathy (HE) by addressing the gut-liver axis, specifically focusing on lactulose or lactitol and rifaximin, while also explaining their mechanisms of action and adverse event profiles.
Read More
Hepatic Encephalopathy: Exploring Alterations in Microbiota Caused by Liver Disease
June 25th 2024Kimberly Brown, MD, explains the role of the gut microbiota in the development of hepatic encephalopathy (HE) and describes the common alterations to the microbiota that occur because of chronic liver disease.
Read More
Preventing Cirrhosis Progression: Gut-Liver Axis, Circulation, Inflammation
June 25th 2024Arun B. Jesudian, MD, discusses strategies to prevent the progression of cirrhosis, which include targeting microbiome abnormalities to improve the gut-liver axis, enhancing circulatory function, treating the inflammatory state, and addressing portal hypertension.
Read More
Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management
June 18th 2024The panel examines the evolving role of primary care clinicians in managing patients with hepatic encephalopathy (HE) and emphasizes the importance of consulting specialists when necessary, providing insights from the perspective of a primary care clinician.
Read More
HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading
June 18th 2024The expert panelists explore the symptoms and risk factors associated with HE, the challenges in diagnosing the condition due to its resemblance to neuropsychiatric l disorders, and the methods used to assess and grade the severity of the disease.
Read More
Educating Primary Care Clinicians on Outpatient HE Management and Ammonia Testing
June 11th 2024Medical experts emphasize the importance of educating primary care clinicians about the outpatient management of hepatic encephalopathy, a common complication of portal hypertension, and highlight the crucial role of ammonia testing in effectively managing the disease.
Read More
Exploring the Impact of Hepatic Encephalopathy on Patients and Their Families
June 11th 2024Pamela Kushner, MD, FAAFP; Nancy Reau, MD; Arun B. Jesudian, MD, and Kimberly Brown, MD, discuss the impact of hepatic encephalopathy (HE) on patients and their families, as well as strategies for improving patient outcomes.
Read More